① How much did SF Express Holdings' supply chain and international business revenue increase by about 20% in November? ② What are the highlights of Yao Ming Kangde's subscription to a European biotechnology private equity fund?
Financial Services Association, December 19 (Editor: Feng Yi) Financial Association brings you today's important announcements on Hong Kong stocks
1) Company news
SF Holdings (06936.HK): The total revenue from express logistics, supply chain and international business in November was RMB 25.196 billion, up 6.73% year on year.
Among them, due to the advance of the e-commerce platform's Double Eleven promotion cycle, this year's peak express delivery business season reached October earlier than last year. Judging from the cumulative data from October to November, the company's express logistics business revenue increased 7.85% year on year, and business volume increased 16.84% year on year.
Benefiting from the high level of international shipping charges and stable cargo volume, and the increase in demand for international air freight, international freight and agency business revenue grew at a relatively high level; the company's supply chain and international business revenue increased by 21.65% year-on-year in November.
Yao Ming Kangde (02359.HK): It is proposed to spend a total of 20 million euros to subscribe to private equity fund shares. The fund focuses on biotech enterprise creation and seed investment activities in Europe, and mature and late-stage startups.
According to the announcement, fund manager Sofinnova Partners is a well-known European biotechnology investment institution with more than 50 years of experience in industry resources and investment management in the European life sciences sector.
Connected Digital (02598.HK): Obtained a license to operate a virtual asset trading platform in Hong Kong.
Goldwind Technology (02208.HK): The subsidiary plans to transfer 100% of the shares of Muniushan Holdings Co., Ltd.
Fu Hong Han Lin (02696): Cooperation and licensing agreement with PALLEON for E-602 and combination therapy.
Shisi Pharmaceutical Group (02005.HK): Signed a framework agreement with Junshengtai Pharmaceutical for joint research and development.
China Biopharmaceutical (01177): The marketing application for bemosubizumab injection combined with anlotinib hydrochloride capsules for the treatment of advanced acinar soft tissue sarcoma was approved.
2) Repurchase dynamics
Times Electric (03898.HK): Canceled the repurchased 4.8873 million H shares.
AIA (01299.HK): Repurchase 4.6258 million shares at HK$0.252 billion at a repurchase price of HK$54.15-54.75.
Tencent Holdings (00700.HK): Spend HK$0.703 billion to repurchase 1.72 million shares at a repurchase price of HK$401.4-421.8.
CSPC Group (01093.HK): Spending HK$29.294 million to repurchase 6.15 million shares at a repurchase price of HK$4.72-4.79.
Samsonite (01910.HK): spent HK$16.2702 million to repurchase 0.7737 million shares at a repurchase price of HK$20.8-21.2.
